The association of tacrolimus concentration, dosage with CYP3A5 genetic polymorphism among renal transplant recipients in Vietnam

  • Hoàng Xuân Sử Học viện Quân y
  • Ha Thanh Binh Vietnam Navy
  • Nguyen Van Khoi Military Medical Academy
  • Pham Quoc Toan Vietnam Navy

Main Article Content

Keywords

CYP3A5, tacrolimus, renal transplant

Abstract

Objective: To analyse the association of concentrations and dose of tacrolimus with CYP3A5 genetic polymorphism during 6 months after kidney transplantation. Subject and method: Eighty-eight kidney transplant recipients treated with tacrolimus, monitored during the first 6 months post transplantation at the 103 Military Hospital from 06/2017 to 10/2021. Blood samples were collected using for routine monitoring of therapeutic drug levels and determination of CYP3A5 genetic polymorphism based on in-house molecular methods. Association of CYP3A5 genetic polymorphism with tacrolimus concentrations, doses, concentrations/doses ratio (C0/D) and eGRF (estimated glomerular filtration rate) was investigated based on CYP3A5 genotypes at T1 (after trasplantation 1 month), T3 (after trasplantation 3 months), T6 (after trasplantation 6 months). Result: Frequency of CYP3A5*3*3, CYP3A5*1*3, and CYP3A5*1*1 genotypes were 43.2%, 46.6% and 10.2%, respectively. Patients with the CYP3A5*1*3, and CYP3A5*1*1 genotype had a lower C0, C0/D ratio and eGRF at T1, T3, T6, whereas daily dose of tacrolimus was higher at T1, T3 and T6, respectively as compared with those of CYP3A5*3*3. There was significant correlation of TAC doses and trough concentrations at corresponding time points of T1, T3 and T6 tested. Conclusion: The relation of CYP3A5 genetic polymorphism with trough concentrations, dose of tacrolimus and eGRF,  provided a valuable tool for individualized dose of tacrolimus in renal transplant population in Vietnam

Article Details

References

1. Cho JH, Yoon YD, Park JY, Song EJ et al (2012) Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant Proc 44(1): 109-114. doi: 10.1016/j.transproceed.2011.11.004.
2. Mac Guad R, Zaharan N, Chik Z, Mohamed Z et al (2016) Effects of CYP3A5 genetic polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 48(1): 81-87. doi: 10.1016/j.transproceed.2016.01.001.
3. Brunet M, Van Gelder T, Åsberg A, Haufroid V et al (2019) Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report. Therapeutic drug monitoring 41(3): 261-307.
4. Xuan NT, Hop VQ, Kien TQ, Toan PQ et al (2022) Frequencies and Association of CYP3A5 Polymorphism With Tacrolimus Concentration Among Renal Transplant Recipients in Vietnam. Transplant Proc 54(8): 2140-2146. doi: 10.1016/j.transproceed.2022.07.009.
5. Zhou Y, Ingelman‐Sundberg M, Lauschke VM (2017) Worldwide distribution of cytochrome P450 alleles: A meta‐analysis of population‐scale sequencing projects. Clinical Pharmacology & Therapeutics 102(4): 688-700.
6. Htun Y, Swe H, Saw T (2018) CYP3A5* 3 genetic polymorphism and tacrolimus concentration in myanmar renal transplant patients. Transplantation proceedings (4): 1034-1040.
7. Zhao Y, Song M, Guan D, Bi S et al (2005) Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplantation proceedings 1: 178-181.
8. Vũ Phương Nhung (2020) Nghiên cứu đa hình/đột biến gen CYP2C9, CYP2C19, CYP3A5 và CYP2D6 Cytochrome P450 ở người kinh ở Việt Nam. Học viện Khoa học và Công nghệ.
9. Veiga MI, Asimus S, Ferreira P, Martins J et al (2009) Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. European journal of clinical pharmacology 65(4): 355-363.
10. Zhang X, Liu ZH, Zheng JM, Chen ZH et al (2005) Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clinical transplantation 19(5): 638-643.
11. Soda M, Fujitani M, Michiuchi R, Shibayama A et al (2017) Association between tacrolimus pharmacokinetics and cytochrome P450 3A5 and multidrug resistance protein 1 exon 21 polymorphisms. Transplantation proceedings, Elsevier (6): 1492-1498.
12. Birdwell KA, Decker B, Barbarino JM, Peterson JF et al (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clinical Pharmacology & Therapeutics 98 (1): 19-24.
13. Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D et al (2013) Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation. Clinical therapeutics 35(11): 1762-1769.

Article Sidebar

PDF (Tiếng Việt)
Published
Feb 9, 2023
DOI: https://doi.org/10.52389/ydls.v18i1.1629
Issue
Volume 18 - No1/2023
Section
Articles
How to Cite
SửH. X., BinhH. T., KhoiN. V., & ToanP. Q. (2023). The association of tacrolimus concentration, dosage with CYP3A5 genetic polymorphism among renal transplant recipients in Vietnam. Tạp Chí Y Dược lâm sàng 108, 18(1). https://doi.org/10.52389/ydls.v18i1.1629